 | • レポートコード：QYR2104Z2760 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、血液がんのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬理療法、幹細胞移植、手術・放射線療法、貧血治療、血栓症治療、ニュートペニア治療、対症療法）、用途別市場規模（免疫、白血病幹細胞病態生理、腎臓病、遺伝病、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・血液がんの市場動向 ・企業の競争状況、市場シェア ・血液がんの種類別市場規模（薬理療法、幹細胞移植、手術・放射線療法、貧血治療、血栓症治療、ニュートペニア治療、対症療法） ・血液がんの用途別市場規模（免疫、白血病幹細胞病態生理、腎臓病、遺伝病、その他） ・血液がんの北米市場規模2016-2027（アメリカ、カナダ） ・血液がんのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・血液がんのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・血液がんの中南米市場規模2016-2027（メキシコ、ブラジル） ・血液がんの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Karyopharm Therapeutics、Johnson & Johnson、Roche Diagnostics A/S、AbbVie、Novartis、Kite Pharma、Celgene Corporation、Abbott Laboratories、Beckman Coulter、HemoCue AB、C. R. Bard、Siemens AG、Sysmex、Mindray Medical International Limited、Bio-Rad Laboratories、The Medicine Company、Pharmacyclics、Horiba、DiagnoCure Inc.、Astellas Pharma US） ・結論 |
hematologic cancer. Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer.
Market Analysis and Insights: Global Hematological Cancers Market
The global Hematological Cancers market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hematological Cancers market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hematological Cancers market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hematological Cancers market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hematological Cancers market.
Global Hematological Cancers Scope and Market Size
Hematological Cancers market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hematological Cancers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutopenia Treatment
Symptomatic treatment
Segment by Application
Epidemiology
Pathophysiology of Leukemic Stem Cells
Kidney Diseases
Genetic Diseases
Other Diseases
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
AbbVie
Novartis
Siemens AG
Sysmex
Mindray Medical International Limited
Bio-Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematological Cancers Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Pharmacological Therapies
1.2.3 Stem Cell Transplantation
1.2.4 Surgery and Radiation Therapy
1.2.5 Anemia Treatment
1.2.6 Thrombosis Treatment
1.2.7 Neutopenia Treatment
1.2.8 Symptomatic treatment
1.3 Market by Application
1.3.1 Global Hematological Cancers Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Epidemiology
1.3.3 Pathophysiology of Leukemic Stem Cells
1.3.4 Kidney Diseases
1.3.5 Genetic Diseases
1.3.6 Other Diseases
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hematological Cancers Market Perspective (2016-2027)
2.2 Hematological Cancers Growth Trends by Regions
2.2.1 Hematological Cancers Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hematological Cancers Historic Market Share by Regions (2016-2021)
2.2.3 Hematological Cancers Forecasted Market Size by Regions (2022-2027)
2.3 Hematological Cancers Industry Dynamic
2.3.1 Hematological Cancers Market Trends
2.3.2 Hematological Cancers Market Drivers
2.3.3 Hematological Cancers Market Challenges
2.3.4 Hematological Cancers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematological Cancers Players by Revenue
3.1.1 Global Top Hematological Cancers Players by Revenue (2016-2021)
3.1.2 Global Hematological Cancers Revenue Market Share by Players (2016-2021)
3.2 Global Hematological Cancers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hematological Cancers Revenue
3.4 Global Hematological Cancers Market Concentration Ratio
3.4.1 Global Hematological Cancers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematological Cancers Revenue in 2020
3.5 Hematological Cancers Key Players Head office and Area Served
3.6 Key Players Hematological Cancers Product Solution and Service
3.7 Date of Enter into Hematological Cancers Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematological Cancers Breakdown Data by Type
4.1 Global Hematological Cancers Historic Market Size by Type (2016-2021)
4.2 Global Hematological Cancers Forecasted Market Size by Type (2022-2027)
5 Hematological Cancers Breakdown Data by Application
5.1 Global Hematological Cancers Historic Market Size by Application (2016-2021)
5.2 Global Hematological Cancers Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Hematological Cancers Market Size (2016-2027)
6.2 North America Hematological Cancers Market Size by Type
6.2.1 North America Hematological Cancers Market Size by Type (2016-2021)
6.2.2 North America Hematological Cancers Market Size by Type (2022-2027)
6.2.3 North America Hematological Cancers Market Size by Type (2016-2027)
6.3 North America Hematological Cancers Market Size by Application
6.3.1 North America Hematological Cancers Market Size by Application (2016-2021)
6.3.2 North America Hematological Cancers Market Size by Application (2022-2027)
6.3.3 North America Hematological Cancers Market Size by Application (2016-2027)
6.4 North America Hematological Cancers Market Size by Country
6.4.1 North America Hematological Cancers Market Size by Country (2016-2021)
6.4.2 North America Hematological Cancers Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Hematological Cancers Market Size (2016-2027)
7.2 Europe Hematological Cancers Market Size by Type
7.2.1 Europe Hematological Cancers Market Size by Type (2016-2021)
7.2.2 Europe Hematological Cancers Market Size by Type (2022-2027)
7.2.3 Europe Hematological Cancers Market Size by Type (2016-2027)
7.3 Europe Hematological Cancers Market Size by Application
7.3.1 Europe Hematological Cancers Market Size by Application (2016-2021)
7.3.2 Europe Hematological Cancers Market Size by Application (2022-2027)
7.3.3 Europe Hematological Cancers Market Size by Application (2016-2027)
7.4 Europe Hematological Cancers Market Size by Country
7.4.1 Europe Hematological Cancers Market Size by Country (2016-2021)
7.4.2 Europe Hematological Cancers Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Hematological Cancers Market Size (2016-2027)
8.2 Asia-Pacific Hematological Cancers Market Size by Type
8.2.1 Asia-Pacific Hematological Cancers Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hematological Cancers Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hematological Cancers Market Size by Type (2016-2027)
8.3 Asia-Pacific Hematological Cancers Market Size by Application
8.3.1 Asia-Pacific Hematological Cancers Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hematological Cancers Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hematological Cancers Market Size by Application (2016-2027)
8.4 Asia-Pacific Hematological Cancers Market Size by Region
8.4.1 Asia-Pacific Hematological Cancers Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hematological Cancers Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hematological Cancers Market Size (2016-2027)
9.2 Latin America Hematological Cancers Market Size by Type
9.2.1 Latin America Hematological Cancers Market Size by Type (2016-2021)
9.2.2 Latin America Hematological Cancers Market Size by Type (2022-2027)
9.2.3 Latin America Hematological Cancers Market Size by Type (2016-2027)
9.3 Latin America Hematological Cancers Market Size by Application
9.3.1 Latin America Hematological Cancers Market Size by Application (2016-2021)
9.3.2 Latin America Hematological Cancers Market Size by Application (2022-2027)
9.3.3 Latin America Hematological Cancers Market Size by Application (2016-2027)
9.4 Latin America Hematological Cancers Market Size by Country
9.4.1 Latin America Hematological Cancers Market Size by Country (2016-2021)
9.4.2 Latin America Hematological Cancers Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematological Cancers Market Size (2016-2027)
10.2 Middle East & Africa Hematological Cancers Market Size by Type
10.2.1 Middle East & Africa Hematological Cancers Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hematological Cancers Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hematological Cancers Market Size by Type (2016-2027)
10.3 Middle East & Africa Hematological Cancers Market Size by Application
10.3.1 Middle East & Africa Hematological Cancers Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hematological Cancers Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hematological Cancers Market Size by Application (2016-2027)
10.4 Middle East & Africa Hematological Cancers Market Size by Country
10.4.1 Middle East & Africa Hematological Cancers Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hematological Cancers Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Karyopharm Therapeutics
11.1.1 Karyopharm Therapeutics Company Details
11.1.2 Karyopharm Therapeutics Business Overview
11.1.3 Karyopharm Therapeutics Hematological Cancers Introduction
11.1.4 Karyopharm Therapeutics Revenue in Hematological Cancers Business (2016-2021)
11.1.5 Karyopharm Therapeutics Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Hematological Cancers Introduction
11.2.4 Johnson & Johnson Revenue in Hematological Cancers Business (2016-2021)
11.2.5 Johnson & Johnson Recent Development
11.3 Roche Diagnostics A/S
11.3.1 Roche Diagnostics A/S Company Details
11.3.2 Roche Diagnostics A/S Business Overview
11.3.3 Roche Diagnostics A/S Hematological Cancers Introduction
11.3.4 Roche Diagnostics A/S Revenue in Hematological Cancers Business (2016-2021)
11.3.5 Roche Diagnostics A/S Recent Development
11.4 AbbVie
11.4.1 AbbVie Company Details
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Hematological Cancers Introduction
11.4.4 AbbVie Revenue in Hematological Cancers Business (2016-2021)
11.4.5 AbbVie Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Hematological Cancers Introduction
11.5.4 Novartis Revenue in Hematological Cancers Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Kite Pharma
11.6.1 Kite Pharma Company Details
11.6.2 Kite Pharma Business Overview
11.6.3 Kite Pharma Hematological Cancers Introduction
11.6.4 Kite Pharma Revenue in Hematological Cancers Business (2016-2021)
11.6.5 Kite Pharma Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Details
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Hematological Cancers Introduction
11.7.4 Celgene Corporation Revenue in Hematological Cancers Business (2016-2021)
11.7.5 Celgene Corporation Recent Development
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Details
11.8.2 Abbott Laboratories Business Overview
11.8.3 Abbott Laboratories Hematological Cancers Introduction
11.8.4 Abbott Laboratories Revenue in Hematological Cancers Business (2016-2021)
11.8.5 Abbott Laboratories Recent Development
11.9 Beckman Coulter
11.9.1 Beckman Coulter Company Details
11.9.2 Beckman Coulter Business Overview
11.9.3 Beckman Coulter Hematological Cancers Introduction
11.9.4 Beckman Coulter Revenue in Hematological Cancers Business (2016-2021)
11.9.5 Beckman Coulter Recent Development
11.10 HemoCue AB
11.10.1 HemoCue AB Company Details
11.10.2 HemoCue AB Business Overview
11.10.3 HemoCue AB Hematological Cancers Introduction
11.10.4 HemoCue AB Revenue in Hematological Cancers Business (2016-2021)
11.10.5 HemoCue AB Recent Development
11.11 C. R. Bard
11.11.1 C. R. Bard Company Details
11.11.2 C. R. Bard Business Overview
11.11.3 C. R. Bard Hematological Cancers Introduction
11.11.4 C. R. Bard Revenue in Hematological Cancers Business (2016-2021)
11.11.5 C. R. Bard Recent Development
11.12 Siemens AG
11.12.1 Siemens AG Company Details
11.12.2 Siemens AG Business Overview
11.12.3 Siemens AG Hematological Cancers Introduction
11.12.4 Siemens AG Revenue in Hematological Cancers Business (2016-2021)
11.12.5 Siemens AG Recent Development
11.13 Sysmex
11.13.1 Sysmex Company Details
11.13.2 Sysmex Business Overview
11.13.3 Sysmex Hematological Cancers Introduction
11.13.4 Sysmex Revenue in Hematological Cancers Business (2016-2021)
11.13.5 Sysmex Recent Development
11.14 Mindray Medical International Limited
11.14.1 Mindray Medical International Limited Company Details
11.14.2 Mindray Medical International Limited Business Overview
11.14.3 Mindray Medical International Limited Hematological Cancers Introduction
11.14.4 Mindray Medical International Limited Revenue in Hematological Cancers Business (2016-2021)
11.14.5 Mindray Medical International Limited Recent Development
11.15 Bio-Rad Laboratories
11.15.1 Bio-Rad Laboratories Company Details
11.15.2 Bio-Rad Laboratories Business Overview
11.15.3 Bio-Rad Laboratories Hematological Cancers Introduction
11.15.4 Bio-Rad Laboratories Revenue in Hematological Cancers Business (2016-2021)
11.15.5 Bio-Rad Laboratories Recent Development
11.16 The Medicine Company
11.16.1 The Medicine Company Company Details
11.16.2 The Medicine Company Business Overview
11.16.3 The Medicine Company Hematological Cancers Introduction
11.16.4 The Medicine Company Revenue in Hematological Cancers Business (2016-2021)
11.16.5 The Medicine Company Recent Development
11.17 Pharmacyclics
11.17.1 Pharmacyclics Company Details
11.17.2 Pharmacyclics Business Overview
11.17.3 Pharmacyclics Hematological Cancers Introduction
11.17.4 Pharmacyclics Revenue in Hematological Cancers Business (2016-2021)
11.17.5 Pharmacyclics Recent Development
11.18 Horiba
11.18.1 Horiba Company Details
11.18.2 Horiba Business Overview
11.18.3 Horiba Hematological Cancers Introduction
11.18.4 Horiba Revenue in Hematological Cancers Business (2016-2021)
11.18.5 Horiba Recent Development
11.18 DiagnoCure Inc.
.1 DiagnoCure Inc. Company Details
.2 DiagnoCure Inc. Business Overview
.3 DiagnoCure Inc. Hematological Cancers Introduction
.4 DiagnoCure Inc. Revenue in Hematological Cancers Business (2016-2021)
.5 DiagnoCure Inc. Recent Development
11.20 Astellas Pharma US
11.20.1 Astellas Pharma US Company Details
11.20.2 Astellas Pharma US Business Overview
11.20.3 Astellas Pharma US Hematological Cancers Introduction
11.20.4 Astellas Pharma US Revenue in Hematological Cancers Business (2016-2021)
11.20.5 Astellas Pharma US Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Hematological Cancers Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Pharmacological Therapies
Table 3. Key Players of Stem Cell Transplantation
Table 4. Key Players of Surgery and Radiation Therapy
Table 5. Key Players of Anemia Treatment
Table 6. Key Players of Thrombosis Treatment
Table 7. Key Players of Neutopenia Treatment
Table 8. Key Players of Symptomatic treatment
Table 9. Global Hematological Cancers Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Hematological Cancers Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Hematological Cancers Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Hematological Cancers Market Share by Regions (2016-2021)
Table 13. Global Hematological Cancers Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Hematological Cancers Market Share by Regions (2022-2027)
Table 15. Hematological Cancers Market Trends
Table 16. Hematological Cancers Market Drivers
Table 17. Hematological Cancers Market Challenges
Table 18. Hematological Cancers Market Restraints
Table 19. Global Hematological Cancers Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Hematological Cancers Market Share by Players (2016-2021)
Table 21. Global Top Hematological Cancers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Cancers as of 2020)
Table 22. Ranking of Global Top Hematological Cancers Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Hematological Cancers Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Hematological Cancers Product Solution and Service
Table 26. Date of Enter into Hematological Cancers Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Hematological Cancers Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Hematological Cancers Revenue Market Share by Type (2016-2021)
Table 30. Global Hematological Cancers Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Hematological Cancers Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Hematological Cancers Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Hematological Cancers Revenue Market Share by Application (2016-2021)
Table 34. Global Hematological Cancers Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Hematological Cancers Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Hematological Cancers Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Hematological Cancers Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Hematological Cancers Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Hematological Cancers Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Hematological Cancers Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Hematological Cancers Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Hematological Cancers Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Hematological Cancers Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Hematological Cancers Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Hematological Cancers Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Hematological Cancers Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Hematological Cancers Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Hematological Cancers Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Hematological Cancers Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Hematological Cancers Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Hematological Cancers Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Hematological Cancers Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Hematological Cancers Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Hematological Cancers Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Hematological Cancers Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Hematological Cancers Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Hematological Cancers Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Hematological Cancers Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Hematological Cancers Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Hematological Cancers Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Hematological Cancers Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Hematological Cancers Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Hematological Cancers Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Hematological Cancers Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Hematological Cancers Market Size by Country (2022-2027) & (US$ Million)
Table 66. Karyopharm Therapeutics Company Details
Table 67. Karyopharm Therapeutics Business Overview
Table 68. Karyopharm Therapeutics Hematological Cancers Product
Table 69. Karyopharm Therapeutics Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 70. Karyopharm Therapeutics Recent Development
Table 71. Johnson & Johnson Company Details
Table 72. Johnson & Johnson Business Overview
Table 73. Johnson & Johnson Hematological Cancers Product
Table 74. Johnson & Johnson Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 75. Johnson & Johnson Recent Development
Table 76. Roche Diagnostics A/S Company Details
Table 77. Roche Diagnostics A/S Business Overview
Table 78. Roche Diagnostics A/S Hematological Cancers Product
Table 79. Roche Diagnostics A/S Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 80. Roche Diagnostics A/S Recent Development
Table 81. AbbVie Company Details
Table 82. AbbVie Business Overview
Table 83. AbbVie Hematological Cancers Product
Table 84. AbbVie Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 85. AbbVie Recent Development
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Hematological Cancers Product
Table 89. Novartis Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 90. Novartis Recent Development
Table 91. Kite Pharma Company Details
Table 92. Kite Pharma Business Overview
Table 93. Kite Pharma Hematological Cancers Product
Table 94. Kite Pharma Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 95. Kite Pharma Recent Development
Table 96. Celgene Corporation Company Details
Table 97. Celgene Corporation Business Overview
Table 98. Celgene Corporation Hematological Cancers Product
Table 99. Celgene Corporation Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 100. Celgene Corporation Recent Development
Table 101. Abbott Laboratories Company Details
Table 102. Abbott Laboratories Business Overview
Table 103. Abbott Laboratories Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 104. Abbott Laboratories Recent Development
Table 105. Beckman Coulter Company Details
Table 106. Beckman Coulter Business Overview
Table 107. Beckman Coulter Hematological Cancers Product
Table 108. Beckman Coulter Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 109. Beckman Coulter Recent Development
Table 110. HemoCue AB Company Details
Table 111. HemoCue AB Business Overview
Table 112. HemoCue AB Hematological Cancers Product
Table 113. HemoCue AB Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 114. HemoCue AB Recent Development
Table 115. C. R. Bard Company Details
Table 116. C. R. Bard Business Overview
Table 117. C. R. Bard Hematological Cancers Product
Table 118. C. R. Bard Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 119. C. R. Bard Recent Development
Table 120. Siemens AG Company Details
Table 121. Siemens AG Business Overview
Table 122. Siemens AG Hematological Cancers Product
Table 123. Siemens AG Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 124. Siemens AG Recent Development
Table 125. Sysmex Company Details
Table 126. Sysmex Business Overview
Table 127. Sysmex Hematological Cancers Product
Table 128. Sysmex Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 129. Sysmex Recent Development
Table 130. Mindray Medical International Limited Company Details
Table 131. Mindray Medical International Limited Business Overview
Table 132. Mindray Medical International Limited Hematological Cancers Product
Table 133. Mindray Medical International Limited Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 134. Mindray Medical International Limited Recent Development
Table 135. Bio-Rad Laboratories Company Details
Table 136. Bio-Rad Laboratories Business Overview
Table 137. Bio-Rad Laboratories Hematological Cancers Product
Table 138. Bio-Rad Laboratories Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 139. Bio-Rad Laboratories Recent Development
Table 140. The Medicine Company Company Details
Table 141. The Medicine Company Business Overview
Table 142. The Medicine Company Hematological Cancers Product
Table 143. The Medicine Company Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 144. The Medicine Company Recent Development
Table 145. Pharmacyclics Company Details
Table 146. Pharmacyclics Business Overview
Table 147. Pharmacyclics Hematological Cancers Product
Table 148. Pharmacyclics Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 149. Pharmacyclics Recent Development
Table 150. Horiba Company Details
Table 151. Horiba Business Overview
Table 152. Horiba Hematological Cancers Product
Table 153. Horiba Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 154. Horiba Recent Development
Table 155. DiagnoCure Inc. Company Details
Table 156. DiagnoCure Inc. Business Overview
Table 157. DiagnoCure Inc. Hematological Cancers Product
Table 158. DiagnoCure Inc. Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 159. DiagnoCure Inc. Recent Development
Table 160. Astellas Pharma US Company Details
Table 161. Astellas Pharma US Business Overview
Table 162. Astellas Pharma US Hematological Cancers Product
Table 163. Astellas Pharma US Revenue in Hematological Cancers Business (2016-2021) & (US$ Million)
Table 164. Astellas Pharma US Recent Development
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hematological Cancers Market Share by Type: 2020 VS 2027
Figure 2. Pharmacological Therapies Features
Figure 3. Stem Cell Transplantation Features
Figure 4. Surgery and Radiation Therapy Features
Figure 5. Anemia Treatment Features
Figure 6. Thrombosis Treatment Features
Figure 7. Neutopenia Treatment Features
Figure 8. Symptomatic treatment Features
Figure 9. Global Hematological Cancers Market Share by Application: 2020 VS 2027
Figure 10. Epidemiology Case Studies
Figure 11. Pathophysiology of Leukemic Stem Cells Case Studies
Figure 12. Kidney Diseases Case Studies
Figure 13. Genetic Diseases Case Studies
Figure 14. Other Diseases Case Studies
Figure 15. Hematological Cancers Report Years Considered
Figure 16. Global Hematological Cancers Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 17. Global Hematological Cancers Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 18. Global Hematological Cancers Market Share by Regions: 2020 VS 2027
Figure 19. Global Hematological Cancers Market Share by Regions (2022-2027)
Figure 20. Global Hematological Cancers Market Share by Players in 2020
Figure 21. Global Top Hematological Cancers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Cancers as of 2020
Figure 22. The Top 10 and 5 Players Market Share by Hematological Cancers Revenue in 2020
Figure 23. Global Hematological Cancers Revenue Market Share by Type (2016-2021)
Figure 24. Global Hematological Cancers Revenue Market Share by Type (2022-2027)
Figure 25. North America Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. North America Hematological Cancers Market Share by Type (2016-2027)
Figure 27. North America Hematological Cancers Market Share by Application (2016-2027)
Figure 28. North America Hematological Cancers Market Share by Country (2016-2027)
Figure 29. United States Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Canada Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Europe Hematological Cancers Market Share by Type (2016-2027)
Figure 33. Europe Hematological Cancers Market Share by Application (2016-2027)
Figure 34. Europe Hematological Cancers Market Share by Country (2016-2027)
Figure 35. Germany Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. France Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. U.K. Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Italy Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Russia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Nordic Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Asia-Pacific Hematological Cancers Market Share by Type (2016-2027)
Figure 43. Asia-Pacific Hematological Cancers Market Share by Application (2016-2027)
Figure 44. Asia-Pacific Hematological Cancers Market Share by Region (2016-2027)
Figure 45. China Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Japan Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. South Korea Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Southeast Asia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. India Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Australia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Latin America Hematological Cancers Market Share by Type (2016-2027)
Figure 53. Latin America Hematological Cancers Market Share by Application (2016-2027)
Figure 54. Latin America Hematological Cancers Market Share by Country (2016-2027)
Figure 55. Mexico Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Brazil Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Middle East & Africa Hematological Cancers Market Share by Type (2016-2027)
Figure 59. Middle East & Africa Hematological Cancers Market Share by Application (2016-2027)
Figure 60. Middle East & Africa Hematological Cancers Market Share by Country (2016-2027)
Figure 61. Turkey Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Saudi Arabia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. UAE Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Karyopharm Therapeutics Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 65. Johnson & Johnson Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 66. Roche Diagnostics A/S Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 67. AbbVie Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 68. Novartis Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 69. Kite Pharma Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 70. Celgene Corporation Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 71. Abbott Laboratories Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 72. Beckman Coulter Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 73. HemoCue AB Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 74. C. R. Bard Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 75. Siemens AG Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 76. Sysmex Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 77. Mindray Medical International Limited Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 78. Bio-Rad Laboratories Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 79. The Medicine Company Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 80. Pharmacyclics Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 81. Horiba Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 82. DiagnoCure Inc. Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 83. Astellas Pharma US Revenue Growth Rate in Hematological Cancers Business (2016-2021)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
世界の非血液がん市場規模・現状・予測（2021年-2027年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…- 世界の非血液がん治療市場規模・現状・予測（2021年-2027年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
- 世界の非血液がん治療市場規模・現状・予測（2021年-2027年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
- 世界の不眠症薬理学的治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Insomnia Pharmacological Treatment Market The global Insomnia Pharmacological Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high …
- 世界の小細胞肺がん治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Small Cell Lung Cancer Treatment Market The global Small Cell Lung Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data…